Valneva

Valneva is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases. The website reports three commercial vaccines, including a single-shot chikungunya vaccine, and clinical candidates against Lyme disease and Shigella.

Its product information is aimed at physicians, pharmacists and other healthcare professionals. The company has a specialist commercial capability for distributing its travel vaccines in key travel vaccine markets, and a manufacturing network with three in-house operations for clinical and commercial production.

The website states that Valneva has more than 650 employees in six countries and lists job openings in Austria (including Vienna), Canada, France, Sweden, the United Kingdom and the United States. Its CEO, Thomas Lingelbach, is described as the founding president and CEO of Valneva. The website does not state a founding year.

Product: Prophylactic vaccines for infectious diseases, including a single-shot chikungunya vaccine, plus travel vaccines and candidates for Lyme disease and Shigella.